Local Access10 min readApril 9, 2026

    Buy Compounded Semaglutide in Chicago: Telehealth vs Local Options (2026)

    Chicago has a growing number of weight loss clinics offering GLP-1 medications — but most charge $300–600 per month. Telehealth brings the same compounded semaglutide to any Chicago neighborhood for $99/month, no clinic visit required.

    Why Chicago Residents Choose Telehealth for GLP-1

    Chicago's healthcare infrastructure is substantial — Northwestern Memorial Hospital, Rush University Medical Center, and the University of Chicago Medicine are among the best in the Midwest. But specialty weight management programs at major hospital systems often involve long wait times and high costs. Meanwhile, the city's independent med-spa and weight loss clinic market has exploded, with prices to match.

    Obesity affects roughly 34% of Chicago adults, according to data from the Chicago Department of Public Health — one of the higher rates among major American cities. The South Side and West Side bear a disproportionate share of this burden, with communities facing limited access to affordable specialty care. Telehealth is not a perfect substitute for comprehensive in-person care, but for ongoing GLP-1 management after an initial evaluation, it closes a significant access gap.

    Chicago GLP-1 Snapshot

    Population: ~2.7 million city / ~9.5 million metro. Adult obesity rate: ~34%. Typical clinic rate for compounded semaglutide: $300–600/mo. Brand Wegovy without insurance: $1,000–$1,400/mo. TRIMI telehealth: $99/mo semaglutide, $125/mo tirzepatide.

    For working Chicagoans — especially those relying on CTA without easy access to car travel — the convenience of telehealth is also a practical benefit. Receiving your medication at your Logan Square apartment or your South Loop high-rise means no clinic commute, no parking fees, and no afternoon off work.

    Local Clinic vs. Telehealth: Pricing Comparison

    Chicago's weight loss clinic market spans the spectrum from hospital-affiliated obesity medicine programs to boutique wellness clinics in neighborhoods like Gold Coast and Lincoln Park. The pricing range reflects this diversity, but one thing is consistent: in-person programs cost significantly more than telehealth alternatives.

    OptionMonthly CostIn-Person VisitInsurance Required
    Chicago Weight Loss Clinic (avg)$300–$600YesSometimes
    Brand Wegovy (no insurance)$1,000–$1,400YesRecommended
    TRIMI Telehealth (compounded)$99/mo (sema) / $125/mo (tirz)NoNo

    At $400/month from a typical Chicago clinic versus $99/month through TRIMI, the annual savings amount to over $3,600. For a 12-month treatment course — the minimum recommended duration for meaningful and sustained GLP-1 results — that's money that stays in your pocket without any compromise in the quality of the medication.

    How Telehealth Works: Consultation to Delivery in Chicago

    Getting started with TRIMI from Chicago is a four-step process designed to be completed from your home, office, or anywhere with a phone or computer.

    Step 1: Online Health Questionnaire

    Complete a secure health intake form covering your medical history, current medications, and weight loss goals. No appointment needed — submit anytime.

    Step 2: Licensed Provider Review

    A licensed Illinois provider reviews your intake, assesses your eligibility for GLP-1 treatment, and creates a starting dose plan tailored to your health profile.

    Step 3: Prescription to Pharmacy

    Your prescription is sent to a licensed compounding pharmacy. Semaglutide $99/mo or tirzepatide $125/mo — flat pricing, no insurance, no hidden fees.

    Step 4: Shipped to Your Chicago Address

    Medication arrives at your door in 3–5 business days, shipped with temperature-controlled packaging. Ongoing care managed through the TRIMI platform.

    Available Medications

    TRIMI offers two compounded GLP-1 medications for Chicago residents:

    Compounded Semaglutide

    $99/month

    • Same active ingredient as Wegovy
    • Weekly self-injection
    • ~15% average weight loss at 68 weeks
    • No insurance required

    Compounded Tirzepatide

    $125/month

    • Dual GLP-1/GIP receptor agonist
    • Weekly self-injection
    • ~22% average weight loss at 72 weeks
    • No insurance required

    Compare your options in our semaglutide vs. tirzepatide guide, or use our GLP-1 selection quiz to find the best fit for your situation.

    Chicago's Health Landscape and the Case for Accessible GLP-1 Care

    Chicago has a well-documented history of health disparities along racial and geographic lines. A 2023 report from the Chicago Department of Public Health found that obesity prevalence was highest in predominantly Black and Latino communities on the South and West Sides, while access to private weight management clinics was concentrated in wealthier North Side and suburban markets.

    GLP-1 medications represent one of the most significant advances in obesity medicine in decades. Making them accessible at $99/month without requiring insurance approval or in-person visits directly addresses the structural barriers that have historically limited their reach in communities that need them most.

    For context, type 2 diabetes affects an estimated 11% of Chicago adults, and hypertension — strongly correlated with obesity — is even more prevalent. GLP-1 medications are now approved for cardiovascular risk reduction in patients with established heart disease, making access to these drugs a medical priority that extends well beyond aesthetics. Read more about the cardiovascular benefits of GLP-1 treatment.

    Getting Started with TRIMI in Chicago

    If you're a Chicago resident with a BMI of 27 or higher (with at least one weight-related health condition) or a BMI of 30 or higher, you may qualify for compounded semaglutide or tirzepatide through TRIMI. The entire process — from intake to first delivery — takes less than a week.

    Start by reviewing whether you meet the criteria for GLP-1 treatment, then complete the online consultation. Your medication will be shipped directly to any Chicago zip code within 3–5 business days.

    Ready to Start in Chicago?

    Access affordable GLP-1 treatment without leaving your neighborhood. Compounded semaglutide starts at $99/month — delivered to any Chicago address, no office visit required.

    Get Started for $99/Month

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medications requiring evaluation by a licensed healthcare provider. Individual results vary. Common side effects include nausea, vomiting, diarrhea, and constipation. Not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Consult your provider before starting any new medication.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. Chicago Department of Public Health. Chicago Health Atlas: Obesity Data. 2023.
    5. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 9, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Compare Columbus GLP-1 clinic pricing to Trimi's $99/mo telehealth semaglutide.

    Compare San Jose GLP-1 clinic pricing to Trimi's $99/mo telehealth semaglutide.

    Start your GLP-1 journey — from $99/mo

    Get Started